Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2025-02-05 00:00:00 ET · period of report 2025-02-03 · accession 0001725160-25-000040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-05 | 2025-02-03 | ZNTL | Paul Andrea | CLO | A - Grant | $0.00 | +934.0K | 1.08M | +623% | $0 |
| D | 2025-02-05 | 2025-02-03 | ZNTL | Paul Andrea | CLO | S - Sale | $1.71 | -13.2K | 1.07M | -1% | -$22.6K |
| D | 2025-02-05 | 2025-02-03 | ZNTL | Paul Andrea | CLO | A - Grant | $0.00 | +124.7K | 124.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-03 | A | A | 934,041 | $0.00 | 1,084,014 | D | — | — | (F1) Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer. |
| 2 | Common | Common Stock | 2025-02-03 | S | D | 13,230 | $1.71 | 1,070,784 | D | — | — | (F2) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-02-03 | A | A | 124,714 | $0.00 | 124,714 | D | $1.68 · — to 2035-02-02 | 124,714 Common Stock | (F3) The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. |